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report less hunger than healthy controls. Endogenous endocannabinoids (eCBs), specifically the anan-
damide, have been associated to hunger, as a meal initiator, but research regarding AN and eCB and
inconclusive. In this pilot study, we investigated plasma levels of eCB in inpatients with AN during
fasting and after eating, both during the acute AN phase and after weight recovery. After an 8-hr fasting
period, blood sample was collected from all participants. After that, participants were given a muffin test
meal. Blood samples for the investigation of endogenous eCBs anandamide (N-arachidonoylethanolamide
[AEA]) and 2-arachidonoylglycerol (2-AG) were then collected after 120 and 240 min. Participants were
only allowed to eat and drink what was offered them during the research. AN reported less hunger than
controls during fasting and at the end of the experiment. Also, plasma levels of AEA were significantly
smaller in AN in comparison with controls in all time points. No significant difference was found for
2-AG plasma levels. After recovery, no significant difference was found for eCB levels. These findings
could be interpreted as an AEA deregulation in AN before and after food intake, which persists after
weight recovery. These findings may have implications to the pharmacological treatment of AN and to
relapse occurring in the disorder.
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Altered circulating endocannabinoids in anorexia nervosa during acute and weight-
restored phases – a pilot study
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by a low food-intake and often 
exceeding exercise, leading to a particularly low body x weight proportion. Patients with AN 
usually report less hunger than healthy controls. Endogenous endocannabinoids (eCB), 
specifically the anandamide, have been associated to hunger, as a meal initiator, but research 
regarding AN and eCB and inconclusive. In this pilot study, we investigated plasma levels of 
eCB in inpatients with anorexia nervosa during fasting and after eating, both during the acute 
AN phase and after weight-recovery. After an 8-hour fasting period, blood sample was collected 
from all participants. After that, participants were given a muffin test meal. Blood samples for 
the investigation of endogenous endocannabinoids anandamide (N-arachidonoylethanolamide, 
AEA) and 2-arachidonoylglycerol (2-AG) were then collected after 120-min and 240-min. 
Participants were only allowed to eat and drink what was offered them during the research. AN 
reported less hunger than controls during fasting and at the end of the experiment. Also, plasma 
levels of AEA were significantly smaller in AN in comparison to controls in all time points. No 
significant difference was found for 2-AG plasma levels. After recovery, no significant 
difference was found for eCB levels. These findings could be interpreted as an AEA 
deregulation in AN before and after food intake, which persists after weight recovery. These 
findings may have implications to the pharmacological treatment of AN and to relapse 
occurring in the disorder.
Highlights
 Anandamide, an endogenous endocannabinoid associated to hunger, is present in less 
quantity in patients with anorexia nervosa during fasting;
 The difference in circulating levels of anandamide between patients with anorexia 
nervosa and healthy controls persists after eating;
 This difference is not normalized after weight-recovery following treatment.
Keywords: Anorexia Nervosa; Fasting; Endocannabinoids; Appetite.
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1 Introduction
Anorexia nervosa (AN) is an eating disorder characterized by a low food-intake 
leading to emaciation, an extremely low body x weight proportion (American Psychiatric 
Association, 2013), with considerable mortality (Keshaviah, et al., 2014). Although the latest 
version of the Diagnostic  Manual of Mental Disorders (DSM-5) does not include over-
exercising as a criterium for the diagnostic of AN (American Psychiatric Association, 2013), it 
has been reported in up to 80% of participants in studies evaluating its prevalence, and 
contributes the low body-weight maintenance (Rizk, et al., 2015).
Eating is controlled by many systems in humans (Enax & Weber, 2016; Lutter & 
Nestler, 2009; Saper, Chou, & Elmquist, 2002), and several of these systems have been reported 
to be impaired in AN, like the reward system, homeostatic system (Keating, Tilbrook, Rossell, 
Enticott, & Fitzgerald, 2012; P. Monteleone, et al., 2006; P. Monteleone, et al., 2005), including 
the endocannabinoid (eCB) system (A. M. Monteleone, et al., 2015; P. Monteleone, et al., 2005; 
Watkins & Kim, 2014). In turn, the eCB system is involved in homeostatic control of several 
physiological functions, including food-intake and exergy expenditure, besides fat storage and 
body mass through mechanisms spread centrally and peripherally located (Marco, Romero-
Zerbo, Viveros, & Bermudez-Silva, 2012). More specifically, two endocannabinoids are mostly 
involved in food-intake: the endogenous ligands anandamide (arachidonoylethanolamide, 
AEA) and 2-arachidonoylglycerol (2-AG), as well as the receptors CB1 and CB2 (Cota, et al., 
2003).
Greater concentrations of eCB in the blood and in the brain were evidenced in several 
disorders, ranging from reproductive, metabolic and gastrointestinal to neurological and 
psychiatric disorders (Di Marzo, Bifulco, & De Petrocellis, 2004), including eating disorders 
(P. Monteleone, et al., 2005) and obesity (Gatta-Cherifi, et al., 2012).
AEA and 2-AG were also found in greater concentration in brain regions in response 
to fasting in rats (Kirkham, Williams, Fezza, & Di Marzo, 2002). Furthermore, fasting also 
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increased AEA levels in peripheral regions (small intestine), and peripheral administration 
(intraperitoneal in rats) of AEA increased food intake (Gomez, et al., 2002). These studies point 
to a consistent role of eCB in food-intake control. Taking that into consideration, a previous 
study assessed eCB plasma levels in outpatients with AN during fasting (P. Monteleone, et al., 
2005), and, unexpectedly found higher plasma AEA levels in AN in comparison to healthy 
controls. These contradictory results might be associated with a lack of control of diet type, as 
the study included outpatients. Besides that, intense exercising also promotes an increase in 
circulating levels of AEA (Heyman, et al., 2012), and exercise-induced eCB levels were not 
possible to be controlled during this study.
A better understanding of the eCB mechanisms related to anorexia nervosa may yield 
important knowledge for the pathophysiology of the disorder, and might help establish whether 
alterations in the eCB system are consistent with the state or trait of the disease (A. M. 
Monteleone, et al., 2015; P. Monteleone, et al., 2005). For such, longitudinal studies must be 
carried out in order to verify if changes observed during the acute phase remain after recovery. 
In that sense, we investigated plasma levels of endogenous endocannabinoids (AEA and 2-AG) 
in inpatients with anorexia nervosa during fasting and after eating, both during the acute AN 
phase and after weight-restoration phase. In line with the general literature on AEA and fasting, 
we expected to find higher levels of AEA during fasting in both groups, with a decreased 
amount in AN in comparison to HC both before and after eating. Furthermore, we expected to 
find no significant changes in 2-AG levels, in line with previous findings.
2 Methods
2.1 Ethics
The study was carried out according to Good Clinical Practice and the Declaration of 
Helsinki. The study protocol was approved by the Ethics Committee of the University of 
Zurich (KEK-ZH-No 2009-0115/1) and registered at ClinicalTrials.gov (trial number 
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NCT00946816). All participants were thoroughly informed on the procedures and provided 
written informed consent.
2.2 Participants
Participants in the AN (n = 15) group met the DMS-V criteria (American Psychiatric 
Association, 2013) for inclusion. They were recruited from an inpatient weight multimodal 
interdisciplinary therapeutic program of the Department of Consultation-Liaison-Psychiatry 
and Psychosomatic Medicine, at the University Hospital Zurich. The experiment consisted of 
two visits. Visit 1 occurred between the second and fourth week after admission, during the 
first phase (orientation) of the therapy. This is the time when patients get used to the clinic 
setting and also have somatic and psychiatric symptoms stabilized. During the first phase, 
patients are not supposed to eat to gain weight, but are oriented to eat regularly.  Goals of the 
therapeutic program are to reach a normalization of weight and eating behaviors. Visit 2 
occurred after AN patients attained BMI >17.5 kg/m2, when they are also close to a minimal 
normal weight (ANR, n = 10, since some of the patients did not gain weight after treatment), 
following a three-month-long multimodal treatment, which aimed at reducing pathological 
eating behaviors, improving body weight, and treating somatic as well as psychiatric 
comorbidities. The therapeutic goal of the unit is to reach BMI > 18.5 kg/m2, but in the last 
phase of the treatment, inpatients are often under pressure to organize their life outside the unit. 
To reduce dropout, we chose a BMI close to the goal, but in a therapeutic phase in which is still 
enough time for the research visit. Furthermore, a 17.5 kg/m2 BMI represents the threshold for 
diagnosing AN (American Psychiatric Association, 2013).
Normal-weight age-matched healthy controls (HC, n = 9) were recruited via public 
announcements. Detailed information on participants can be found on Table 1. Exclusion 
criteria included a history of drug or alcohol abuse, a history of gastrointestinal disorders (since 
it has been reported they can increase AEA concentrations (Di Marzo, et al., 2004)), and the 
presence of mental disorders (other than AN for the AN group). Participants also underwent a 
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gastro-interstinal Magnetic Resonance Imaging, and further exclusion criteria in relation to that 
can be found in Bluemel, et al. (2017).
*******insert table 1*******
2.3 Procedure
All procedures were done in the acute and then the weight-restored phase with AN 
patients. Participants completed the Beck Depression Inventory (BDI), an inventory used for 
assessing depression levels (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). Self-report of 
hunger was assessed every 15 minutes during the first two hours, and every 30 minutes during 




After an 8-hour fasting period, blood sample was collected from all participants. After 
that, participants were given a muffin test meal (430 kcal, 21% fat, 63% carbohydrate, 16% 
protein). The choice of the meal was related to a companion study on gastric motor and sensory 
functions (Bluemel, et al., 2017), and participants were supposed to eat it while seated on the 
MRI scanner, prior to the scanning sessions (reported in Bluemel, et al., 2017). All participants 
fully ate the given muffin. Blood samples were then collected after 120-min and 240-min (Fig. 
1). Participants were only allowed to eat and drink what was offered them during the research. 
Blood for the investigation of endogenous endocannabinoids anandamide (N-
arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG) was drawn into pre-
cooled 2 ml K-EDTA tubes (Greiner Bio-One VACUETTE®, St. Gallen, Switzerland). 
Immediately after the tube was filled, phenylmethanesulfonylfluoride (PMSF) solved in 
methanol was added to a final concentration of 0.5 mM to avoid degradation of 
endocannabinoids. Tubes were centrifuged at 4°C with 1750 G for 10 minutes. Supernatants 
were collected into 2 ml tubes (Rotilabo®, Carl Roth AG, Arlesheim, Switzerland) and stored 
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at -80°C until measurement. Plasma samples were thawed on ice and 500 µl of the samples 
were extracted with 2.5 volumes of toluene after adding internal standards (AEA-d8, 2-AG-d8 
and 1AG-d5). Samples were mixed thoroughly and phases were separated by centrifugation for 
5 min at 4 °C and 10.000 rpm. The organic layer was transferred to a new tube and the extraction 
was repeated. The combined organic phases were dried under a stream of nitrogen after addition 
of 10 µl of trapping solution (30% glycerol in methanol). The residues were reconstituted in 
100 ul of 50% acetonitrile, pelleted for 10 min at 10.000 g, and transferred to glass vials for 
LC-MS/MS analysis. Because of the endogenous levels of endocannabinoids in biological 
matrices, calibration curves (concentrations ranging from 0.1 to 50 pmol/ml) were prepared in 
a substitute matrix (phosphate buffered saline containing 0.5 mg/ml bovine serum albumin, pH 
7.4) to test for linearity and extraction efficiencies.
LC-MS/MS analyses. The sample separation was performed on a Phenomenex Gemini-
NX-C18 reverse phase column (2.3 x 150 mm, 5 m pore size) with a corresponding opti-gard 
pre-column on an Agilent 1100 liquid chromatography system. The mobile phase consisted of 
(A) 4 mM ammonium acetate and (B) 95% methanol, 5% acetonitrile containing 4 mM 
ammonium acetate at a flow rate of 300 l/min using an injection volume of 60 l. An isocratic 
flow of 87% B was held for 11 min. The HPLC system was coupled to a 4000 QTRAP hybrid 
triple quadrupole linear ion trap mass spectrometer (Applied Biosystems) equipped with a 
TurboV source and electrospray (ESI) interface. Analytes were recorded using multiple reaction 
monitoring (-MRM) in negative mode using the following source specific parameters: IS -
4500V, TEM 450°C, curtain gas (CUR = 30), nebulizer gas (GS1 = 50), heater gas (GS2 = 70) 
and collision gas (CAD = 10). The compound specific parameters for the different substrates 
were determined by direct infusion of standard solutions (100-300 nmol/ml) in acetonitril at a 
flow rate of 10 µl/min using the quantitative optimization function of Analyst software 1.5.2. 
LOQ for AEA and 2-AG in plasma were estimated to 0.2 and 0.1 pmol/ml, respectively. 
Extraction efficiencies for AEA and 2-AG were on average 60%.
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Acyl migration. In contrast to AEA, 2-AG undergoes acyl migration to its regioisomer 
1-AG under acidic conditions. Certain organic solvents used for the extraction from biological 
matrices further facilitate this process. While 2-AG is almost completely converted to 1-AG in 
ethanol, a conversion to 1-AG in toluene is negligible (2011, Zoerner et.al). 2-AG and 1-AG 
(eluting approximately 0.5 min after 2-AG) were separated under chromatographic conditions, 
and samples contained on average 5% 1-AG.
2.4 Data analyses and statistics
Statistical analyses were performed using IBM SPSS Statistics 25 (IBM Corp., 
Armonk, NY, USA). Mixed model analyses were performed for 2AG and AEA including group 
(AN; HC) and time (fasting; 120 min after meal; 240 min after meal) as fixed factors. A first-
order ante-dependence covariance structure was accommodated for the repeated observations. 
For the longitudinal analyses, full factorial models were fitted including the disorder phase 
(acute and weight restored) and time (fasting, 120-min after meal, 240-min after meal) as fixed 
factors. A first-order factor analytic covariance structure was accommodated for the repeated 
observations. In all models, subject was specified as a random factor. Bonferroni-corrected 
pairwise comparisons of the estimated marginal means were used as post-hoc tests. Finally, the 
psychological measures were correlated with the eCB measures during fasting.
3 Results
3.1 Self-report of hunger
We found significant effect of group x time interaction (F(1, 383.0) = 2.254, p < 0.05). 
HC reported more hunger than AN during fasting and 240-min after eating. There was no 
significant difference for other time points (Fig.2).
*******insert figure 2*******
3.2 Endocannabinoid measurements
3.2.1 Acute phase of AN
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Anandamide (AEA). There were main effects of group (F(1, 22.1) = 29.11, p < 0.001), 
time (F(2, 22.3) = 47.81, p < 0.001) as well as an interaction of group x time (F(2, 22.3) = 5.46, p = 
0.012). HC showed higher concentrations of AEA than AN (p < 0.001) (Fig. 4a). Across groups, 
concentrations of AEA were higher in the fasting condition than 120 min and 240 min (p < 
0.001) after the meal. The group x time interaction revealed that, although HC showed higher 
concentrations of AEA at all time points (p < 0.001), the difference between groups was 
significantly stronger in the fasting condition (Δ = 5.180, p < 0.001) than 120 min (Δ = 1.801, 
p < 0.001) or 240 min after meal (Δ = 1.948, p < 0.001) (Fig. 3a).
2-arachidonoylglycerol (2-AG). No main or interactive effects of group and time were 
found for 2AG. Means and standard errors can be seen in Figure 3b, 3d.
Depression and eCB. Depression scores at BDI were negatively correlated to plasma 
levels of AEA (r = -.62, p < 0.001) and positively correlated to 2-AG (r = .639, p < 0.001) 
during fasting. 
3.2.2 Comparison of eCB between the acute and weight-restored phases
Anandamide (AEA). We found a significant main effect of time (F(2, 8.9) = 43.67, p < 
0.001), but no main effect of disorder phase was found (p = 0.75) Figure 3c. Across disorder 
phases, concentrations of AEA were higher in the fasting condition (p < 0.001) and 240 min (p 
< 0.05) after meal.
2-arachidonoylglycerol (2-AG). No significant main effects or interactions were found 





We investigated plasma levels of endogenous endocannabinoids in patients with 
anorexia nervosa during fasting and after eating, in acute and weight-restored phases. To our 
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best knowledge, this is the first study carried out with inpatients with acute AN and weight-
restored patients. Higher plasma levels of anandamide were found in healthy controls in 
comparison to patients with anorexia nervosa. Also, higher concentrations were found during 
fasting in comparison to after 120 and 240 minutes following a standard meal in both groups, 
with stronger effect during fasting. These results were specific for AEA, as we did find 
significant results for 2-AG. Finally, we found no significant difference in eCB levels between 
the acute and weight-restored phases.
Lower plasma levels of AEA in AN in comparison to HC are in line with our 
hypothesis and compatible to the hunger self-report. This is in line with previous studies that 
have reported AEA as a physiological meal initiator (Gatta-Cherifi, et al., 2012). In their study, 
Gatta-Cherifi, et al. (2012) showed increased plasma levels of AEA during fasting in healthy 
controls and people with obesity, with only healthy controls’ AEA decreasing after eating. They 
also did not find significant change in 2-AG levels. Given the fact that hunger levels are 
decreased in AN in comparison to controls (Bluemel, et al., 2017; Piccolo, et al., 2019) and 
also here, and AEA increases food-intake (Gomez, et al., 2002), it is possible to infer that low 
food intake in AN may be due to a deregulation in the eCB system, more specifically, the AEA. 
Furthermore, cannabis-based treatments have shown to increase food-intake of highly palatable 
food (Foltin, Fischman, & Byrne, 1988), and patients with AN show lower palatability rating 
in comparison to controls (Keating, et al., 2012).
When examining eCB changes across phases of the disorder, our results showed no 
significant changes in circulating eCB levels across conditions (acute vs weight-restored). No 
eCB difference between acute and restored patients with AN were also reported by (A. M. 
Monteleone, et al., 2015), suggesting deranged eCB levels (mainly AEA) might remain present 
even after recovery. It is important to note that the previous study focused on evaluating 
differences in circulating eCB levels in response to pleasant vs non-pleasant food. In that study, 
patients were given the chance to choose between favorite and non-favorite foods, and the type 
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of meal was used as an independent variable. In response to hedonic eating, no differences were 
found for AEA, but 2-AG levels were shown to be deranged in AN. Our study failed to show 
differences in 2-AG levels across groups, but this may be related to the difference in 
methodology (with Monteleone’s et al., 2015 using meal as a factor, and changes in 2-AG being 
associated to hedonic eating, which was not measured in our study). New studies with larger 
samples are necessary for resolving this issue.
Interestingly, AEA do not reach with the normalization of weight the values of the 
control group. This could indicate that an eCB deregulation may consist of a trait, and not 
simply a state of AN. One possible explanation could be related to exaggerate exercising in the 
disorder. Over-exercising could represent a compensatory behavior in an attempt to regulate 
AEA levels, since exercising increases circulating AEA levels, as previously mentioned 
(Heyman, et al., 2012). A recent clinical case report showed a significant reduction in the urge 
to engage in physical activity in a male patient with AN treated with an eCB agonist, without 
major side effects (Graap, Erim, & Paslakis, 2018), pointing to the direction that overexercising 
could be a compensatory response to a diminished availability of eCB.  In that sense, Kron, 
Katz, Gorzynski, and Weiner (1978) show, for instance, that intense exercising remains present 
even after recovery in people with a history of AN. These findings could also be related to 
eating regulation processes and might explain the high relapse rates (Carter, et al., 2012). Since 
no change occurs in eCB circulating levels, these patients would continue with a decreased 
appetite in comparison to healthy controls, leading to a reduced food intake, which would 
contribute to the below-average body weight (Mayer, Schebendach, Bodell, Shingleton, & 
Walsh, 2012).
Depression levels were negatively correlated to AEA, and positively correlated to 2-
AG in our study. In other words, low levels of AEA were associated to higher levels of 
depression. This is in line with previous results reporting a positive correlation between 2-AAG 
and depression scores in pain patients (La Porta, et al., 2015). In addition, a recent study on rats 
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showed that low doses of AEA were successful in reversing depression-like behaviors (de 
Morais, et al., 2016). The altered levels of AEA could therefore be a factor contributing to the 
high rates of comorbidity between AN and depressive disorders. It has been reported that up to 
75% of the individuals with an eating disorder may experience depression (Association, 2006).
This study is not without limitations. First, our sample sizes were small, and Visit 2 
counted with less participants. Larger studies should be carried out in order to further strengthen 
these findings. Second, we did not measure other forms of eCB concentrations (such as in brain 
regions involved in the motivation to eat). These data could provide better understanding 
between the relationship of AEA and appetite control. Also, future research should focus on 
establishing the relationship between AEA levels and intensity of exercise. Moreover, it would 
be interesting to see AEA levels in longitudinal studies evaluating larger periods after the 
recovery to establish how far these traits can go, and measure to what extent relapse and the 
eCB system are related.
In conclusion, our findings show an AEA deregulation in AN before and after food 
intake, which persists after weight restoration. These findings may have implications to the 
pharmacological treatment of AN and to relapse occurring in the disorder. Cannabinoid 
treatments have significantly improved appetite in several disorders (Beal, et al., 1995; Nelson, 
Walsh, Deeter, & Sheehan, 1994), including AN (Badowski & Yanful, 2018). A recent review 
on the use of Dronabinol, a synthetic form of Δ-9-tetrahydrocannabinol, an exocannabinoid, 
concluded that this treatment could be beneficial for patients with AN and other conditions 
involving low food-intake. Taken together, these findings should foment the development and 
larger clinical trials involving eCB agonists for the treatment of AN and other appetite-related 
disorders.
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Figures
Figure 1. Study procedure. After fasting for an 8-hour period, participants had their blood 
sample collected. Following a standard meal, the same procedure was repeated after 120-min 
and 240-min.
Figure 2. Self-report of hunger in healthy controls (HC) and patients with anorexia nervosa 
(AN). Significant difference was found during fasting and 240-min after a standardized meal.
Figure 3. Circulating endoccanabinoids across time points (Fasting, 120-min and 240-min after 
eating a standard meal). A. Anandamide’s (AEA) levels were significant higher for HC in 
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comparison to AN in all time points, and the difference was higher during fasting in comparison 
to the other time points (p < 0.001). B. No significant difference was found for circulating levels 
of 2-Arachidonylglycerol (2-AG) between groups (p > 0.05). C. Circulating levels of AEA in 
AN during acute and weight-restored  phase. There was no significant difference between both 
phases (p > 0.05). There was a significant difference between fasting and the other time points 
(P < 0.01) in both pahses. D. No significant difference was found for circulating levels of 2-
Arachidonylglycerol (2-AG) between phases (p > 0.05).
Figure 4. Total circulating levels of endocannabinoids across groups and anorexia nervosa 
phase. A. Higher anandamide’s (AEA) concentration was found in healthy controls (HC) in 
comparison to participants with anorexia nervosa (AN) in general (p < 0.001). No significant 
difference was found for 2-Arachidonylglycerol (2-AG) between groups (*p > 0.05). B. No 
significant difference was found for AEA or 2-AG across phases (acute and weight-restored) 
in patients with AN.
Tables
Table 1. Description of study population. Body mass index (BMI), the Beck Depression 
Inventory (BDI) scores, and the State-Trait Anxiety Inventory (STAI) scores for healthy 
controls (HC), patients with anorexia nervosa during the acute phase (AN), and weight-restored 
patients at the end of treatment (ANR).
Table 2. Means and standard errors for plasma levels of endocannabinoids (pmol/ml) in healthy 
controls (HC), patients with anorexia nervosa during the acute phase (AN), and weight-restored 
patients at the end of treatment (ANR).

























Demographic data are given as mean; descriptive data are given as mean ± standard error.












Anandemide 5.83 ± 0.44 2.85 ± 0.34 2.81 ± 0.22
(AEA) pmol/ml    
















Arachidonoylglycerol 3.05 ± 0.45 2.34 ± 0.35 1.97 ± 0.21
(2-AG) pmol/ml    
Fasting 2.91 ± 0.27 1.72 ± 0.21 1.45 ± 0.23
120-min 3.23 ± 0.64 2.75 ± 0.51 2.35 ± 0.31
240-min 3.01 ± 0.55 2.56 ± 0.44 2.11 ± 0.20
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